MedTrace Logo

A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

NCT00692458 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-08-12

No results posted yet for this study

Summary

The purpose of this study is to test MK0822 on reducing the risk of bone metastasis in women with breast cancer.

Conditions

Interventions

DRUG

Comparator: odanacatib

odanacatib; 5mg oral, once daily for approximately 60 months.

DRUG

Comparator: placebo

placebo; oral, once daily for approximately 60 months

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-09-30
Completion
2008-09-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00692458 on ClinicalTrials.gov